Moneycontrol PRO
HomeNewsBusinessMarketsCipla tumbles 3% after Samina Hamied steps down as VC

Cipla tumbles 3% after Samina Hamied steps down as VC

Hamied will continue to remain associated with the company as a non-executive director who is liable to retire by rotation.

January 29, 2024 / 09:41 IST
Cipla also approved the appointment of Balram Bhargava as an additional and independent director for a period of five years until March 31, 2029.
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Shares of Cipla slipped 3 percent in opening trade on January 29 after Samina Hamied stepped down from her role as the executive vice-chair of the company. However, she will continue to remain associated with the company as a non-executive director who is liable to retire by rotation.

    The drugmaker stated that the transition in Hamied's role is part of a larger promoter strategy aimed at transforming Cipla into a completely professionally managed company like conglomerates such as the Tata Group.

    The company approved the appointment of Balram Bhargava as an additional and independent director for five years until March 31, 2029.

    Bhargava is a prominent figure in global public health leadership and has actively championed the south-south cooperation, advocated for equitable healthcare access, supported the democratisation of scientific research, and fostered public-private collaboration to introduce new technologies and cost-effective innovative products into healthcare systems. He also brings more than 35 years of experience to the table.

    Follow our market blog to catch all the live action

    At 9.20am, the shares of Cipla were trading at Rs 1,326 on the NSE. Some profit-booking also seeped into the counter, pulling the stock lower as it has run up over 7 percent in the past month, buoyed by its robust Q3 results.

    On that account, brokerage firm Nomura has downgraded the stock to a 'neutral' rating, with a price target of Rs 1,427 as it sees limited upside in the counter given its recent run-up and a lack of new near-term catalysts.

    The firm also sees the approval and launch timeline of key drugs, Advair and Abraxane in the US, which are caught in regulatory snags, as the key monitorables for Cipla.

    Also read | Cipla's Samina Hamied steps down as executive vice chairperson citing personal commitments

    Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

     

    Moneycontrol News
    first published: Jan 29, 2024 09:36 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347